<DOC>
	<DOCNO>NCT01865617</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose laboratory treat T cell see well work treat patient chronic lymphocytic leukemia , non-Hodgkin lymphoma , acute lymphoblastic leukemia come back responded treatment . T cell treat laboratory give back patient may make body build immune response kill cancer cell .</brief_summary>
	<brief_title>Laboratory Treated T Cells Treating Patients With Relapsed Refractory Chronic Lymphocytic Leukemia , Non-Hodgkin Lymphoma , Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate feasibility safety adoptive T cell therapy use ex vivo expand autologous CD8 positive ( + ) CD4+ CD19 chimeric antigen receptor ( CAR ) -T cell patient advance CD19+ B cell malignancy . SECONDARY OBJECTIVES : I . To determine duration vivo persistence adoptively transfer T cell , phenotype persist T cell . II . To determine adoptively transfer T cell traffic bone marrow function vivo . III . To determine adoptive transfer CD19 CAR-T cell result depletion CD19+ B cell vivo surrogate functional activity . IV . To determine adoptive transfer CD19 CAR-T cell antitumor activity patient measurable tumor burden prior T cell transfer . V. To determine adoptive transfer CD19 CAR-T cell associated tumor lysis syndrome . OUTLINE : This phase I , dose-escalation study autologous CD19 CAR T-cells follow phase II study . Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cell intravenously ( IV ) 20-30 minute day 0 . Treatment may repeat 21 day without additional lymphodepleting chemotherapy persistent disease absence unacceptable toxicity . DOSE DENSE EXPANSION COHORT : An additional cohort receive second anti-CD19-CAR lentiviral vector-transduced autologous T cell infusion without additional lymphodepleting chemotherapy 10-21 day first infusion adequate CD19 CAR-T cell produce appropriate criterion meet . After completion study treatment , patient follow least 15 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>INCLUSIONS FOR SCREENING AND LEUKAPHERESIS : Patients CD19 express acute lymphoblastic leukemia ( ALL ) , chronic lymphocytic leukemia ( CLL ) nonHodgkin lymphoma ( NHL ) Ability understand provide inform consent Not human immunodeficiency virus ( HIV ) infect INCLUSIONS FOR CART CELL THERAPY Patients : CLL beyond first remission fail combination chemoimmunotherapy regimens contain purine analogue antiCD20 antibody eligible therapy ; patient fludarabine refractory disease eligible ; patient may treat follow allogeneic hematopoietic cell transplant ( HCT ) Indolent NHL mantle cell NHL beyond first remission previously treat chemoimmunotherapy eligible therapy ; patient relapse follow autologous allogeneic HCT eligible Aggressive NHL diffuse large Bcell lymphoma ( DLBCL ) , relapse residual disease follow treatment curative intent ; patient relapse follow , eligible highdose therapy autologous HCT ; patient chemotherapy refractory disease marrow involvement comorbidities preclude successful autologous HCT eligible ; patient may treat follow allogeneic HCT Patients CD19 express , relapse refractory ALL Confirmation diagnosis Evidence CD19 expression immunohistochemistry flow cytometry prior current tumor specimen high likelihood CD19 expression base disease histology Karnofsky performance status &gt; = 60 % All patient childbearing potential must willing use contraceptive method , , least two month T cell infusion Ability understand provide inform consent EXCLUSIONS FOR CART CELL THERAPY Patients require ongoing daily corticosteroid therapy dose &gt; 15 mg prednisone per day ( equivalent ) ; pulse corticosteroid use disease control acceptable Active autoimmune disease require immunosuppressive therapy exclude unless discuss Principal Investigator ( PI ) Serum creatinine &gt; 2.5 mg/dL Serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 5 x upper limit normal Bilirubin &gt; 3.0 mg/dL Patients clinically significant pulmonary dysfunction , determine medical history physical exam undergo pulmonary function testing ; force expiratory volume one second ( FEV1 ) &lt; 50 % predict excluded Diffusing capacity lung carbon monoxide ( DLCO ) ( correct ) &lt; 40 % exclude Significant cardiovascular abnormality define one following : New York Heart Association ( NYHA ) class III IV congestive heart failure , clinically significant hypotension , uncontrolled symptomatic coronary artery disease , document ejection fraction &lt; 35 % Uncontrolled active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>